Hoyland, it doesn't look like we are getting any data as we had hoped. Don't we deserve the biopsy data by now? It was the same old presentation, for the most part. The only working assumption is that the data has to be decent or the FDA wouldn't have them continue the trial after the first two patients. Not exactly anything to excite the retail investor, yet again.
